文献速递肿瘤 PET/CT核素与放射性配体治疗

瑞戈非尼相关急性胰腺炎的18F-FDG PET/CT诊断

Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一名23岁转移性骨肉瘤患者,在接受瑞戈非尼治疗6个月后,18F-FDG PET/CT显示胰腺尾部坏死性占位性病变伴FDG摄取。影像后患者出现上腹痛及血清淀粉酶、脂肪酶升高,排除其他病因后确诊瑞戈非尼诱导的胰腺炎。提示医师应认识酪氨酸激酶抑制剂罕见且可能临床沉默的不良反应。

要点

  • 瑞戈非尼治疗6个月后PET/CT可发现胰腺尾部坏死性病变伴FDG摄取。
  • 影像后出现上腹痛及胰酶升高,排除其他病因确诊药物性胰腺炎。
  • 酪氨酸激酶抑制剂相关胰腺炎可能临床沉默,需结合PET/CT识别。

核心结论

  • 瑞戈非尼可导致急性胰腺炎,18F-FDG PET/CT可显示胰腺尾部坏死性占位伴FDG摄取。

研究设计与样本

  • 本文为单例病例报告,患者为23岁转移性骨肉瘤男性,常规化疗进展后接受瑞戈非尼治疗。

主要发现

  • 瑞戈非尼治疗6个月后,18F-FDG PET/CT显示胰腺尾部坏死性占位性病变伴FDG摄取。
  • 影像后患者出现上腹痛,血清淀粉酶和脂肪酶升高,无其他胰腺炎病因,确诊瑞戈非尼诱导的胰腺炎。

临床怎么用

  • 医师应警惕酪氨酸激酶抑制剂如瑞戈非尼相关的急性胰腺炎,认识18F-FDG PET/CT表现以指导临床管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 23-year-old man with metastatic osteosarcoma, with disease progression on conventional chemotherapy, was treated with regorafenib, a multikinase inhibitor. After treatment for 6 months with regorafenib, 18F-FDG PET/CT scan demonstrated FDG uptake in a necrotic space-occupying lesion involving tail of pancreas. After imaging, patient described symptoms of epigastric pain with elevated serum amylase and lipase levels, confirming diagnosis of regorafenib-induced pancreatitis, because patient had no other causative factors of pancreatitis. Physicians should be aware of rare and possibly clinically silent adverse effects of tyrosine kinase inhibitors, like acute pancreatitis, and recognize the 18F-FDG PET/CT findings to guide appropriate clinical management.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pereira M, Prakash A, Puranik AD, et al. Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT. Clin Nucl Med. 2021. PMID: 33315679. doi:10.1097/RLU.0000000000003449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。